600513.SH
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.64
−6.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 2.7B | 2.2B | 2.2B | 2.0B |
| Cost of Revenue | 2.0B | 1.8B | 1.1B | 1.1B | 912.1M |
| Gross Profit | 898.1M | 943.6M | 1.1B | 1.0B | 1.0B |
| Operating Expenses | |||||
| R&D Expense | 211.7M | 205.3M | 154.6M | 132.1M | 92.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 200.3M | 183.7M | 144.8M | 119.5M | 116.8M |
| Selling & Marketing Expense | 460.8M | 501.5M | 613.9M | 591.6M | 604.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 928.3M | 943.7M | 956.5M | 888.6M | 852.3M |
| Cost and Expenses | 2.9B | 2.7B | 2.1B | 2.0B | 1.8B |
| Operating Income (EBIT) | (40.7M) | (10.4M) | 131.0M | 174.8M | 187.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (118.5M) | (87.6M) | 130.4M | 175.0M | 189.1M |
| Income Tax Expense | (14.3M) | (3.5M) | 24.0M | 23.7M | 22.6M |
| Bottom Line | |||||
| Net Income | (115.0M) | (98.3M) | 84.2M | 135.0M | 141.4M |
| Earnings from Cont. Ops | (104.2M) | (84.2M) | 106.4M | 151.3M | 166.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (115.0M) | (98.3M) | 84.2M | 135.0M | 141.4M |
| Per Share | |||||
| Basic EPS | (CN¥0.40) | (CN¥0.34) | CN¥0.29 | CN¥0.47 | CN¥0.49 |
| Diluted EPS | (CN¥0.40) | (CN¥0.34) | CN¥0.29 | CN¥0.47 | CN¥0.49 |
| Revenue Per Share | CN¥9.01 | CN¥9.38 | CN¥7.44 | CN¥7.57 | CN¥6.78 |
| Shares | |||||
| Basic Shares Outstanding | 321.2M | 289.2M | 290.2M | 287.3M | 288.5M |
| Diluted Shares Outstanding | 321.2M | 289.2M | 290.2M | 287.3M | 288.5M |
| Profitability Metrics | |||||
| EBITDA | — | 88.1M | 192.2M | 232.0M | 229.2M |
| D&A | — | 98.5M | 61.2M | 57.3M | 42.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026